AVROBIO, Inc.
http://www.avrobio.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AVROBIO, Inc.
Avrobio Plots Comeback With Early Data From Gaucher’s Gene Therapy
Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.
Keeping Track: Psoriasis Gets New Topical In Arcutis’ Zoryve; Cidara Submits IV Antifungal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: US FDA Receives Advanced Biologic BLAs From ImmunityBio, CSL; Nymox, Medac Stumble
The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AVROBIO, Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice